Higher concentrations of kynurenic acid in CSF are associated with the slower clinical progression of Alzheimer's disease
Alzheimer's & Dementia · 2023-12 · 19 (12) · 5573-5582
DOI: 10.1002/alz.13162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 02.06.2023. Verfasst von Anne-Brita Knapskog und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: South-Eastern Norway Regional Health Authorities, Cure Alzheimer's Fund, the Research Council of Norway.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION The kynurenine pathway's (KP) malfunction is closely related to Alzheimer's disease (AD), for antagonistic kynurenic acid (KA) and agonistic quinolinic acid act on the N ‐methyl‐D‐aspartate receptor, a possible therapeutic target in treating AD. METHODS In our longitudinal case–control study, KP metabolites in the cerebrospinal fluid were analyzed in 311 patients with AD and 105 cognitively unimpaired controls. RESULTS Patients with AD exhibited higher concentrations of KA (β = 0.18, P < 0.01) and picolinic acid (β = 0.20, P < 0.01) than the controls. KA was positively associated with tau pathology (β = 0.29, P < 0.01), and a higher concentration of KA was associated with the slower progression of dementia. DISCUSSION The higher concentrations of neuroprotective metabolites KA and picolinic acid suggest that the activation of the KP's neuroprotective branch is an adaptive response in AD and may be a promising target for intervention and treatment. Highlights Patients with Alzheimer's disease (AD) exhibited higher concentrations of kynurenic acid and picolinic acid than controls. Higher concentrations of kynurenic acid were associated with slower progression of AD. Potential neurotoxic kynurenines were not increased among patients with AD. Activation of the kynurenine pathway's neuroprotective branch may be an adaptive response in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.
- Department of Geriatric Medicine, University of Oslo, Oslo, Norway.
- Bevital AS, Bergen, Norway.
- Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway.
- The Norwegian Centre on Healthy Ageing (NO-Age), University of Oslo and Akershus University Hospital, Lørenskog, Norway.
- Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.
Förderung
- South-Eastern Norway Regional Health Authorities
- Cure Alzheimer's Fund
- the Research Council of Norway
- Norwegian Health Association
- Nasjonalforeningen for Folkehelsen
Zitieren
APA
Knapskog, A. B., Aksnes, M., Edwin, T. H., Ueland, P. M., Ulvik, A., Fang, E. F., Eldholm, R. S., Halaas, N. B., Saltvedt, I., Giil, L. M., & Watne, L. O. (2023). Higher concentrations of kynurenic acid in CSF are associated with the slower clinical progression of Alzheimer's disease. Alzheimer's & Dementia, 19(12), 5573-5582. https://doi.org/10.1002/alz.13162
Vancouver
Knapskog AB, Aksnes M, Edwin TH, Ueland PM, Ulvik A, Fang EF, et al. Higher concentrations of kynurenic acid in CSF are associated with the slower clinical progression of Alzheimer's disease. Alzheimer's & Dementia. 2023;19(12):5573-5582. doi:10.1002/alz.13162
BibTeX
@article{Knapskog2023,
author = {Knapskog, Anne-Brita and Aksnes, Mari and Edwin, Trine Holt and Ueland, Per Magne and Ulvik, Arve and Fang, Evandro Fei and Eldholm, Rannveig Sakshaug and Halaas, Nathalie Bodd and Saltvedt, Ingvild and Giil, Lasse M and Watne, Leiv Otto},
title = {Higher concentrations of kynurenic acid in CSF are associated with the slower clinical progression of Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2023},
volume = {19},
number = {12},
pages = {5573--5582},
doi = {10.1002/alz.13162}
}
EUVIMED